0.00Open0.15Pre Close0 Volume0 Open Interest10.00Strike Price0.00Turnover76.71%IV20.98%PremiumOct 18, 2024Expiry Date0.00Intrinsic Value100Multiplier21DDays to Expiry0.15Extrinsic Value100Contract SizeAmericanOptions Type0.1920Delta0.1775Gamma55.93Leverage Ratio-0.0102Theta0.0008Rho10.74Eff Leverage0.0055Vega
Pulmonx Stock Discussion
Pulmonx Announces Presentation of Clinical Data from the AeriSeal® CONVERT Trial and 5-Year Follow-up Data from the LIBERATE Study at the European Respiratory Society Congress 2024
Pulmonx (Nasdaq: LUNG) presented clinical data from two significant studies at the European Respiratory Society Congress 2024. The AeriSeal® CONVERT trial showed that 77.6% of patients with collateral ventilation (CV+) successfully converted to CV- status after treatment with the AeriSeal System...
No comment yet